Table 1:
Patient characteristics, overall and by TIDS delays
| All Patients N= 159 | TIDS Delay 34(21.4%) | No Delay 125(78.6%) | p-value* | |
|---|---|---|---|---|
|
| ||||
| Age | ||||
| Median(Mean) | 66(65.8) | 67.5(68.8) | 65(64.9) | 0.05 |
| Range | 43–87 | 44–86 | 43–87 | |
|
| ||||
| BRCA Mutations | ||||
| No mutation | 101(63.5%) | 24(70.6%) | 77(61.6%) | 0.67 |
| BRCA mut/VUS | 28(17.6%) | 5(14.7%) | 23(18.4%) | |
| missing | 30(18.9%) | 5(14.7%) | 25(20%) | |
|
| ||||
| Stage at Diagnosis | ||||
| III | 50(31.4%) | 7(20.6%) | 43(34.4%) | 0.148 |
| IV | 109(68.6%) | 27(79.4%) | 82(65.6%) | |
|
| ||||
| Histology | ||||
| High grade serous | 153(96.2%) | 33(97.1%) | 120(96%) | 1 |
| Other | 6(3.8%) | 1(2.9%) | 5(4%) | |
|
| ||||
| BMI (6 missing) | ||||
| Median(Mean) | 25.5(27.5) | 24.1(27.3) | 25.9(27.6) | 0.239 |
| Range | 15.4–60.1 | 18.4–46.8 | 15.4–60.1 | |
|
| ||||
| CA125 Cycle 1 (46 missing) | ||||
| Median(Mean) | 1170(3203.3) | 1043(3700.9) | 1182.5(3061.9) | 0.939 |
| Range | 4–38600 | 95–38600 | 4–29680 | |
|
| ||||
| CA125 Pre-surgery (80 missing) | ||||
| Median(Mean) | 42(163.1) | 44.5(174.1) | 41(132.9) | 0.571 |
| Range | 1–1901 | 1–1901 | 4–749 | |
|
| ||||
| Charlson Score | ||||
| Median(Mean) | 8(8.5) | 9(8.8) | 8(8.4) | 0.102 |
| Range | 6–12 | 6–12 | 6–12 | |
|
| ||||
| Albumin (1 missing) | ||||
| Median(Mean) | 3.8(3.7) | 3.8(3.7) | 3.8(3.7) | 0.872 |
| Range | 2.3–4.9 | 2.3–4.8 | 2.3–4.9 | |
|
| ||||
| KPS (47 missing) | ||||
| Median(Mean) | 80(80.6) | 80(79.5) | 80(80.9) | 0.874 |
| Range | 50–100 | 50–90 | 50–100 | |
|
| ||||
| Reason for Neoadjuvant Chemotherapy | ||||
| Disease Extent | 111(69.8%) | 22(64.7%) | 89(71.2%) | 0.724 |
| Comorbidity | 8(5%) | 1(2.9%) | 7(5.6%) | |
| Both | 32(20.1%) | 9(26.5%) | 23(18.4%) | |
| Other | 8(5%) | 2(5.9%) | 6(4.8%) | |
|
| ||||
| Chemotherapy Regimen | ||||
| Weekly Paclitaxel/Carboplatin | 121(76.1%) | 25(73.5%) | 96(76.8%) | 0.658 |
| Others | 38(23.9%) | 9(26.5%) | 29(23.2%) | |
|
| ||||
| Preoperative Cycles | ||||
| Median(Mean) | 4(4.2) | 6(4.9) | 4(4) | 0.003 |
| Range | 2–7 | 3–6 | 2–7 | |
|
| ||||
| Dose Reduction | ||||
| No | 142(89.3%) | 30(88.2%) | 112(89.6%) | 0.762 |
| Yes | 17(10.7%) | 4(11.8%) | 13(10.4%) | |
|
| ||||
| TIDS (days) | ||||
| Median(Mean) | 34(36.9) | 48(56.7) | 32(31.4) | - |
| Range | 15–139 | 43–139 | 15–42 | |
|
| ||||
| TNACT (days) | ||||
| Median(Mean) | 19(22.3) | 22(28.8) | 17(20.6) | 0.014 |
| Range | 2–92 | 6–77 | 2–92 | |
|
| ||||
| TPOC (days) † | ||||
| Median(Mean) | 31(33.4) | 37(39.4) | 30(32.2) | 0.01 |
| Range | 13–87 | 15–84 | 13–87 | |
|
| ||||
| Complete Gross Resection | ||||
| No | 53(33.3%) | 11(32.4%) | 42(33.6%) | 1 |
| Yes | 106(66.7%) | 23(67.6%) | 83(66.4%) | |
|
| ||||
| Optimal Debulking | ||||
| No | 20(12.6%) 4 | 7(20.6%) | 13(10.4%) | 0.143 |
| Yes | 139(87.4%) | 27(79.4%) | 112(89.6%) | |
*
p value is obtained by using Fisher-exact test for categorical variables and Wilcoxon rank sum test for continuous variables
†
Only for the patients who received postoperative chemotherapy